A new therapeutic concept, which utilizes dynorphin-based gene therapy, has been developed and could suppress seizures at their site of origin and on demand.
A blood test that measures the amount of cfDNA has been indicated to be correlated with how patients will progress following a glioblastoma diagnosis.
New research presented at SfN Neuroscience 2019 outlines some of the exciting developments and important limitations in the use of brain organoids as models for human cortical development.
Three studies presented at SfN Neuroscience 2019 have shed light on the complex interplay between microglia in neuroinflammation and disease pathology in mice.
Three studies presented at SfN Neuroscience 2019 reveal advancements in autism research that could improve intervention and treatment.
Four studies presented at SfN Neuroscience have demonstrated how the microbiome interacts with the brain in mice, revealing the possible mechanisms behind gut–brain communication.
Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
Abstracts presented at SfN Neuroscience 2019 have revealed that metabolic disturbances in the brain could exacerbate and forewarn Alzheimer’s pathology in mice.
A recent study on the relationship between the huntingtin mutation and astrocytes has revealed that inhibition of the mutation in the glial cells could stop disease progression.